WATERTOWN, Mass. — October 3, 2025 — Leads & Copy — Werewolf Therapeutics, Inc. (Nasdaq: HOWL) will present three posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, held November 5-9, 2025, in National Harbor, Maryland.
The presentations will feature:
- Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity (Abstract 861, Nov. 7).
- Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity (Abstract 964, Nov. 8).
- Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation (Abstract 862, Nov. 8).
Werewolf Therapeutics is focused on developing conditionally activated therapeutics designed to stimulate the immune system for cancer and other immune-mediated conditions, utilizing its PREDATOR® platform to create INDUKINE™ and INDUCER™ molecules.
Investor Contact:
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
Source: Werewolf Therapeutics, Inc.
